stockrowAlkermes plc
ALKS Healthcare Drug Manufacturers Specialty & Generic
Alkermes plc’s revenue for fiscal 2025 (year ended December 2025) was $1.5 billion, down 5.25% from fiscal 2024.
- Revenue
- +21.8%
- EPS
- −80.6%
- Free cash flow
- +6.78%
Quarter to September 2026, against a year earlier
Follow ALKS
Alert me
Alkermes plc (ALKS) Return on invested capital
Alkermes plc's return on invested capital over the twelve months to 30 September 2026 was 1.54%, down 30.2 percentage points from fiscal 2025 (31.8%). Over the past ten years it has ranged from −13.3% (fiscal 2019) to 36.9% (fiscal 2024); the current reading is higher than 82% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 0.00% and above the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | 31.8% | (5.11) |
| FY2024 | 36.9% | 0.91 |
| FY2023 | 36.0% | 36.47 |
| FY2022 | −0.52% | (7.53) |
| FY2021 | 7.01% | 16.95 |
| FY2020 | −9.94% | 3.31 |
| FY2019 | −13.3% | (6.45) |
| FY2018 | −6.80% | 2.00 |
| FY2017 | −8.80% | 4.30 |
| FY2016 | −13.1% | (0.69) |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| SUPN Indivior Pharmaceuticals Inc. compare | 283.0% |
| LQDA Liquidia Corporation compare | 121.1% |
| KNSA Kiniksa Pharmaceuticals International, plc compare | 57.7% |
| LNTH Lantheus Holdings, Inc. compare | 14.6% |
| AMRX AMNEAL PHARMACEUTICALS, INC. compare | 8.45% |
| RDY Dr. Reddy's Laboratories Ltd compare | 4.77% |
| ALKS Alkermes plc | 1.54% |
| ELAN Elanco Animal Health Incorporated compare | 0.51% |
| HIMS Hims & Hers Health, Inc. compare | −11.4% |
| Drug Manufacturers Specialty & Generic industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)
More on ALKS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement